Intravitreal Aflibercept for Treatment-Resistant Neovascular Age-Related Macular Degeneration – Corrected Proof
Objective: To assess the effectiveness of intravitreal aflibercept in patients with neovascular age-related macular degeneration (AMD) previously resistant to treatment with other anti–vascular endothelial growth factor agents.Design: Prospective, open-label, noncontrolled, registered clinical trial.Participants: Forty-nine patients with treatment-resistant neovascular AMD.Intervention: A dose of 2 mg intravitreal aflibercept was administered as 3 initial loading doses every 4 weeks (week 0, week 4, and week 8), followed by further injections every 8 weeks (weeks 16 and 24) across a 24-week period in total. All patients underwent a complete ophthalmic examination, including measurement of Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA), (Read more...)